1321 |
Fundamental Limitations of the Mechanical Guidewire in CTO-PCI |
Kenichiro Shimoji |
Apr. 08. 22 |
1320 |
CTO PCI in CHIP: What¡¯s the Difference? |
Yue Li |
Apr. 08. 22 |
1319 |
Functional Assessment: Is It Necessary in CHIP-PCI? |
Lei Song |
Apr. 08. 22 |
1318 |
Best Device and Innovation Concepts: TCT 2021 & THT 2022 |
Juan F. Granada |
Apr. 08. 22 |
1317 |
Economic Outcomes of TAVR vs SAVR for Low-Risk Patients: Results from the PARTNER 3 Trial |
David Joel Cohen |
Apr. 08. 22 |
1316 |
FAVOR III China: A Sham-controlled Randomized Trial Comparing QFR-Guided and Angiography-Guided PCI |
Bo Xu |
Apr. 08. 22 |
1315 |
iFR-SWEDEHEART: Five-year Outcomes of a Randomized Trial of iFR-guided vs. FFR-guided PCI |
Matthias Gotberg |
Apr. 08. 22 |
1314 |
Clinical Impact of Patient-Prosthesis Mismatch After TAVR |
Duk-Woo Park |
Apr. 08. 22 |
1313 |
Optimal Management for Failure TAVR Valve |
Vinayak Bapat |
Apr. 08. 22 |
1312 |
Optimal TAVR Procedure for Bicuspid AV: Self Expandable Device |
Eberhard Grube |
Apr. 08. 22 |